INC Research/inVentiv Health to Present at Upcoming Jefferies 2017 London Healthcare Conference
RALEIGH, N.C. – November 2, 2017 – INC Research/inVentiv Health (Nasdaq: INCR), the only fully integrated biopharmaceutical solutions organization, today announced that Chief Executive Officer Alistair Macdonald is scheduled to present at the Jefferies 2017 London Healthcare Conference. Mr. Macdonald’s presentation is scheduled for Thursday, November 16, 2017 at 10:00 a.m. GMT.
Links to INC Research/inVentiv Health’s live presentation and archived audio replay, as well as the presentation materials, will be available via the Company’s Investor Relations website at investor.incresearch.com.
About INC Research/inVentiv Health
INC Research/inVentiv Health (Nasdaq:INCR) is the only fully integrated biopharmaceutical solutions organization. Our company, including a Contract Research Organization (CRO) and Contract Commercial Organization (CCO), is purpose-built to address new market realities where clinical and commercial share expertise, data and insights to accelerate biopharmaceutical performance. With more than 22,000 employees and the ability to support customers in more than 110 countries, our global scale and deep therapeutic alignment enables INC Research/inVentiv Health to help customers successfully navigate an increasingly complex environment. For more information, visit incresearch.com or inventivhealth.com.
To learn more about how inVentiv Health experts can help you, please contact us by clicking here.Contact Us
inVentiv Health has been made aware of an internet scam targeting job seekers who have posted their resumes on job posting websites. Scammers are contacting applicants via email and purporting to represent inVentiv Health. Many of these scammers are using Gmail accounts and Google Hangouts to communicate with applicants. All correspondence with us comes from an internal employee with a valid @inventivhealth.com email address. Anyone who suspects they have been solicited in this scam should contact the FBI at ic3.gov.